These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 9827819)

  • 1. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience.
    Manteiga R; Martino R; Sureda A; Labeaga R; Brunet S; Sierra J; Rabella N
    Bone Marrow Transplant; 1998 Nov; 22(9):899-904. PubMed ID: 9827819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan.
    Kanda Y; Mineishi S; Saito T; Seo S; Saito A; Suenaga K; Ohnishi M; Niiya H; Nakai K; Takeuchi T; Kawahigashi N; Shoji N; Ogasawara T; Tanosaki R; Kobayashi Y; Tobinai K; Kami M; Mori S; Suzuki R; Kunitoh H; Takaue Y
    Bone Marrow Transplant; 2001 Feb; 27(4):437-44. PubMed ID: 11313674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation.
    Yanada M; Yamamoto K; Emi N; Naoe T; Suzuki R; Taji H; Iida H; Shimokawa T; Kohno A; Mizuta S; Maruyama F; Wakita A; Kitaori K; Yano K; Hamaguchi M; Hamajima N; Morishima Y; Kodera Y; Sao H; Morishita Y
    Bone Marrow Transplant; 2003 Oct; 32(8):801-7. PubMed ID: 14520425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
    Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
    Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
    Hazar V; Kansoy S; Küpesiz A; Aksoylar S; Kantar M; Yeşilipek A
    Bone Marrow Transplant; 2004 May; 33(9):931-5. PubMed ID: 15034541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
    Trenschel R; Ross S; Hüsing J; Ottinger H; Elmaagacli A; Roggendorf M; Schaefer UW; Runde V
    Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.
    Tormo N; Solano C; Benet I; Clari MA; Nieto J; de la Cámara R; López J; López-Aldeguer N; Hernández-Boluda JC; Remigia MJ; Garcia-Noblejas A; Gimeno C; Navarro D
    Bone Marrow Transplant; 2010 Mar; 45(3):543-9. PubMed ID: 19617905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience.
    Piñana JL; Martino R; Barba P; Margall N; Roig MC; Valcárcel D; Sierra J; Rabella N
    Bone Marrow Transplant; 2010 Mar; 45(3):534-42. PubMed ID: 19668235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
    Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or =10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients.
    Verkruyse LA; Storch GA; Devine SM; Dipersio JF; Vij R
    Bone Marrow Transplant; 2006 Jan; 37(1):51-6. PubMed ID: 16284613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early treatment of CMV antigenemia with ganciclovir for prevention of fatal CMV disease in patients receiving marrow from HLA-matched unrelated donors.
    Shimokawa T; Morishima Y; Kitaori K; Kato C; Sao H
    Int J Hematol; 1999 Aug; 70(2):119-26. PubMed ID: 10497851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR.
    Schulenburg A; Watkins-Riedel T; Greinix HT; Rabitsch W; Loidolt H; Keil F; Mitterbauer M; Kalhs P
    Bone Marrow Transplant; 2001 Oct; 28(8):765-8. PubMed ID: 11781628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [pp65 antigenemia in evaluation of cytomegalovirus infection after kidney transplantation].
    Orlić P; Dvornik S; Husnjak SC; Aralica M; Orlić L; Zivcić-Cosić S; Sladoje-Martinović B; Fućak M
    Acta Med Croatica; 2003; 57(1):49-52. PubMed ID: 12876863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
    Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
    Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
    Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
    Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
    Moretti S; Zikos P; Van Lint MT; Tedone E; Occhini D; Gualandi F; Lamparelli T; Mordini N; Berisso G; Bregante S; Bruno B; Bacigalupo A
    Bone Marrow Transplant; 1998 Jul; 22(2):175-80. PubMed ID: 9707026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation.
    Asano-Mori Y; Oshima K; Sakata-Yanagimoto M; Nakagawa M; Kandabashi K; Izutsu K; Hangaishi A; Motokura T; Chiba S; Kurokawa M; Hirai H; Kanda Y
    Bone Marrow Transplant; 2005 Nov; 36(9):813-9. PubMed ID: 16151428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
    Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
    Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.